22 July 2025
Top hires for Q2-2025
In the second quarter of 2025 Coulter Partners drove global executive search for a wide range of life sciences, health, and technology organizations.
We successfully placed executives for venture capital & private equity-backed firms, alongside large-cap, mid-cap, and public companies, filling critical roles across diverse disciplines worldwide.
CEO/ C-suite/ Board
Function |
Focus area |
Ownership |
Location |
CEO |
ADC oncology company |
VC-backed |
UK |
CEO |
Immuno-oncology therapeutics |
Publicly listed |
US |
CEO |
Sustainable chemical biomanufacturing |
VC-backed |
Sweden |
CEO |
Exosome technologies |
VC-backed |
Italy |
Chief Commercial Officer |
Cell therapy biotech |
Publicly listed |
US |
Chief Business Officer/ Chief Financial Officer |
Epigenetics |
VC-backed |
US |
Chief Financial Officer |
Small molecule therapeutics |
VC-backed |
US |
Chair |
Healthtech |
VC-backed |
US |
Board Director |
Specialized healthcare manufacturing |
Publicly listed |
Australia |
Board Director |
Obesity therapeutics |
Publicly listed |
US |
Board Director |
Oncology therapeutics |
VC-backed |
Australia |
Board Director |
Antibody platform technologies |
VC-backed |
Canada |
Commercial/Functional/Strategic
Function |
Focus area |
Ownership |
Location |
VP, Sales & Marketing Europe |
Surgical technologies |
Privately owned |
Germany |
VP, Strategy (Diagnostics) |
Genetic testing |
Publicly listed |
US |
VP, Global Marketing |
CDMO |
Large operating subsidiary |
US |
Country Chief Financial Officer |
Healthcare services |
PE-backed |
Germany |
General Manager, Europe |
Cell therapy biotech |
Publicly listed |
US |
General Manager & Alliance Lead, International Markets |
Biopharmaceuticals |
Publicly listed |
US |
Global IT Director |
Specialty pharma |
Family owned |
Italy |
Corporate HR Director |
Hormonal health |
Family owned |
France |
Senior Director, Commercial Operations |
Medical devices |
Publicly listed |
Netherlands |
R&D/Medical/Technical
Function |
Focus area |
Ownership |
Location |
Chief Scientific Officer |
AI-enabled CNS therapeutics |
VC-backed |
US |
Chief Technology Officer |
Neuromodulation devices |
VC-backed |
UK |
VP, Head Translational Development |
Genomic technologies |
VC-backed |
Spain |
VP, Combination Product |
Multinational biotech |
Publicly listed |
US |
AVP, Technical Operations |
Life-extending technologies |
Publicly listed |
US |
Head Clinical Safety |
Specialty pharma |
Privately owned |
France |
Global Head Toxicology |
Laboratory & consulting services |
PE-backed |
Germany |
Global Medical Affairs |
Medical apparatus leader |
Publicly listed |
France |
Investor/ Not for Profit/ Accelerator/ Other
Function |
Focus area |
Location |
Senior General Partner |
Science & research VC |
Germany |
Venture Partner |
Life sciences investor |
Denmark |
Investment Professional |
Life sciences investor |
US |
Director of Venture Creation |
Leading university |
UK |
Related
-
Events
19th Bioshares Biotech Summit
07 August 2025 – 08 August 2025
-
Company News
LSX World Congress conference with Justine McIlroy, Client Partner
12 May 2023
-
Thought Leadership
Five Shifts to Digital Personalized Healthcare
10 May 2023
-
Company News
Digital Health UK CEO and Commercial Leaders Breakfast
28 March 2023
